WHAT IS CLAIMED IS:

1. A pharmaceutical composition multi-unit dosage form comprising at least three discrete unit dosage forms bound to one another by a coating and/or matrix, each of said unit dosage forms comprising a therapeutically active agent and an absorption enhancer, said unit dosage forms together comprising a therapeutically effective amount of said therapeutically active agent and an effective amount of said absorption enhancer, wherein said coating and/or matrix dissolves in gastric fluid within no more than 5 minutes to thereby release said unit dosage forms upon oral administration, wherein said absorption enhancer is selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl)aminobutanoic acid) and salts thereof, wherein at least 50 weight percent of the unit dosage forms consists of said absorption enhancer, and wherein said therapeutically active agent is a polypeptide having a molecular weight in a range of 0.5 kDa to 100 kDa.

2. The multi-unit dosage form according to claim 1, comprising from 3 to 10 of said discrete unit dosage forms.

3. The multi-unit dosage form according to claim 1 or 2, wherein said polypeptide is selected from the group consisting of parathyroid hormone and a fragment thereof which exhibits a biological activity of parathyroid hormone.

4. Use of the multi-unit dosage form of any one of claims 1 to 3 in the manufacture of medicament for the treatment of a condition treatable by oral administration of said therapeutically active agent in a subject in need thereof.

5. A use of a pharmaceutical composition unit dosage form comprising a therapeutically active agent and an absorption enhancer, in the manufacture of a medicament for the treatment of a condition treatable by said therapeutically active agent,

said medicament being for concomitant oral administration of at least three of the unit dosage form within a span of no more than 60 minutes, wherein said at least three of said unit dosage form together comprise a therapeutically effective amount of said therapeutically active agent and an effective amount of said absorption enhancer, wherein said absorption enhancer is selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4-chlorobenzoyl)aminobutanoic acid) and salts thereof, wherein at least 50 weight percent of the unit dosage form consists of said absorption enhancer, and wherein said therapeutically active agent is a polypeptide having a molecular weight in a range of 0.5 kDa to 100 kDa.

6. The use according to claim 5, wherein said medicament is for concomitant oral administration of from 3 to 10 of the unit dosage form.

7. The unit dosage form for use according to claim 5 or 6, wherein said polypeptide is selected from the group consisting of parathyroid hormone and a fragment thereof which exhibits a biological activity of parathyroid hormone.

8. Use of a pharmaceutical composition unit dosage form comprising less than 200 μg of parathyroid hormone or a fragment thereof which exhibits a biological activity of parathyroid hormone, and an absorption enhancer selected from the group consisting of NAC (8-N-(2-hydroxybenzoyl)aminocaprylate), NAD (10-N-(2-hydroxybenzoyl)aminodecanoic acid), 5-CNAC (8-N-(5-chlorosalicyloyl)aminocaprylic acid), 4-MOAC (8-N-(2-hydroxy-4-methoxybenzoyl)aminocaprylic acid), 4-CNAB (4-N-(2-hydroxy-4- chlorobenzoyl)aminobutanoic acid) and salts thereof, in the manufacture of a medicament for the treatment of a condition treatable by said parathyroid hormone or a fragment thereof, said medicament being for concomitant oral administration of at least three of said unit dosage form within a span of no more than 60 minutes, wherein said at least three of said unit dosage form together comprise a therapeutically effective amount

of said parathyroid hormone or said fragment thereof and an effective amount of said absorption enhancer.

9. The use according to claim 8, wherein said condition treatable by said parathyroid hormone or a fragment thereof is selected from the group consisting of hypoparathyroidism, osteoporosis, and a medical condition associated with a bone fracture and/or bone defect.